Want to see OTLC full AI Analyst Report?
Top Page
Oncotelic Therapeutics
(OTC:OTLC)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.03
▲(0.00% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily pressured by weak financial performance (minimal recurring revenue, persistent operating losses, and ongoing cash burn with low earnings quality) and dilution/financing risk from recent convertible funding. Technicals are neutral-to-weak with limited momentum, and valuation metrics provided do not support an earnings-based or income-driven case.
Positive Factors
Cancer Therapeutics Focus
A defined focus on cancer and therapeutic development gives OTLC a clear strategic identity within biotechnology. If its candidates advance successfully, this specialized orientation could support differentiated intellectual property and create opportunities for milestone, licensing, or product revenue.
Negative Factors
Pre-Revenue Operating Model
Very limited and inconsistent revenue means the business has not yet demonstrated a dependable commercial engine. Recurring operating losses increase reliance on future product development success and external funding, while making earnings and business performance less predictable over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Cancer Therapeutics Focus
A defined focus on cancer and therapeutic development gives OTLC a clear strategic identity within biotechnology. If its candidates advance successfully, this specialized orientation could support differentiated intellectual property and create opportunities for milestone, licensing, or product revenue.
Read all positive factors
Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.34M
Dividend YieldN/A
Average Volume (3M)206.31K
Price to Earnings (P/E)<0.1
Beta (1Y)-0.06
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding457,512,800
10 Day Avg. Volume271,524
30 Day Avg. Volume206,307
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncotelic Therapeutics Business Overview & Revenue Model
Company Description
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound de...
Oncotelic Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
45
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 250.00K | 0.00 | 0.00 | 70.00K | 0.00 | 0.00 |
| Gross Profit | 250.00K | 0.00 | 0.00 | 70.00K | -12.84K | -61.51K |
| EBITDA | -499.93B | 198.05B | -3.55M | -7.16M | -5.60M | -9.06M |
| Net Income | 247.50M | 249.28M | -4.52B | -7.90M | 17.82M | -11.39M |
Balance Sheet | ||||||
| Total Assets | 10.00T> | 10.00T> | 26.68M | 30.01M | 36.12M | 23.61M |
| Cash, Cash Equivalents and Short-Term Investments | 186.01B | 88.86B | 86.13K | 170.41K | 241.45K | 568.77K |
| Total Debt | 16.16T | 16.27T | 13.09M | 12.57M | 11.26M | 8.99M |
| Total Liabilities | 10.00T> | 10.00T> | 19.20M | 18.40M | 16.92M | 15.45M |
| Stockholders Equity | 10.00T> | 10.00T> | 8.25M | 12.13M | 19.41M | 7.96M |
Cash Flow | ||||||
| Free Cash Flow | -1.52M | -1.38T | -740.27K | -1.32M | -1.45M | -4.43M |
| Operating Cash Flow | -1.52M | -1.38T | -740.27K | -1.32M | -1.45M | -4.43M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.62M | 1.39T | 656.00K | 1.25M | 1.13M | 4.53M |
Oncotelic Therapeutics Technical Analysis
Negative
0.03
Price Trends
0.04
Negative
0.04
Negative
0.05
Negative
Market Momentum
>-0.01
Positive
43.37
Neutral
47.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.37 is Neutral, neither overbought nor oversold. The STOCH value of 47.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLC.
Oncotelic Therapeutics Risk Analysis
Oncotelic Therapeutics disclosed 38 risk factors in its most recent earnings report. Oncotelic Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oncotelic Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $36.37M | 0.63 | 940.81% | ― | -48.76% | -3.02% | |
47 Neutral | $44.18M | -1.67 | -35.78% | ― | ― | -43.60% | |
46 Neutral | $24.35M | -1.18 | -456.35% | ― | ― | 9.68% | |
44 Neutral | $80.30M | -2.08 | -211.15% | ― | ― | -7.28% | |
43 Neutral | $14.82M | -0.31 | 3398.40% | ― | ― | 15.37% | |
41 Neutral | $14.34M | 0.05 | <0.01% | ― | ― | ― |
* Healthcare Sector Average
OTLC
Oncotelic Therapeutics
0.03
-0.02
-40.38%
GRCE
Grace Therapeutics
2.10
-1.14
-35.19%
LTRN
Lantern Pharma
1.91
-2.15
-53.08%
CALC
CalciMedica
2.17
-13.28
-85.95%
ELUT
Elutia
0.82
-1.06
-56.33%
MAIA
MAIA Biotechnology, Inc.
1.32
-0.27
-16.98%
Oncotelic Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Oncotelic Announces New Convertible Note Financing Agreement
Negative
Aug 4, 2026
On August 3, 2026, Oncotelic Therapeutics entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a $178,410 convertible promissory note with a 12% original issue discount and 12% annual interest. The note can be con...
Business Operations and StrategyExecutive/Board Changes
Oncotelic Therapeutics Grants Performance-Based Restricted Stock Units
Positive
Jul 15, 2026
On July 10, 2026, Oncotelic Therapeutics, Inc. approved the grant of 17,796 restricted stock units to its directors, officers, employees, and advisors, each RSU convertible into one share of Series A Convertible Preferred Stock and ultimately into...
Business Operations and StrategyRegulatory Filings and Compliance
Oncotelic Therapeutics Provides Internal Corporate Update Presentation
Neutral
Jul 15, 2026
On July 13, 2026, Oncotelic Therapeutics, Inc. delivered a corporate presentation to its employees, directors, officers and advisors, outlining company information in a formal setting. The materials were furnished to stakeholders through a Form 8-...
Business Operations and StrategyPrivate Placements and Financing
Oncotelic Therapeutics Enters New Convertible Note Financing
Neutral
Jun 29, 2026
On June 23, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a $178,410 convertible promissory note carrying a 12% original issue discount and 12% annual interest, maturing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.